Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-12Y Gel for Tuberous Sclerosis Skin Lesions
NCT05495425Phase 3Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sirolimus in angiofibroma (2 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Improvements in angiofibroma at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
sirolimus
03
Conditions
angiofibroma
Beyond the preview
Go deeper on NCT05495425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495425.